The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients

Journal of Breath Research

Volumn 8, Issue 2, 2014, Pages

  Shepherd, S F ^a   McGuire, N D ^a   De Lacy Costello, B P J ^a   Ewen, R J ^a   Jayasena, D H ^b   Vaughan, K ^a   Ahmed, I ^b   Probert, C S ^c   Ratcliffe, N M ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

artificial neural networks; bio sensing; gas chromatography; inflammatory bowel disease; irritable bowel syndrome

Indexed keywords

METAL OXIDE; METAL; OXIDE;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FECES ANALYSIS; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENSOR; CASE CONTROL STUDY; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; EQUIPMENT; FECES; GENETIC PROCEDURES; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY;

ADULT; BIOSENSING TECHNIQUES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, GAS; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MALE; METALS; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); OXIDES; REPRODUCIBILITY OF RESULTS;

EID: 84899503671     PISSN: 17527155     EISSN: 17527163     Source Type: Journal    
DOI: 10.1088/1752-7155/8/2/026001     Document Type: Article

References (39)

1. Khor B, Gardet A and Xavier R J 2011 Genetics and pathogenesis of inflammatory bowel disease Nature 474 307-17
2. Salzman N H and Bevins C L 2008 Negative interactions with the microbiota: IBD Adv. Exp. Med. Biol. 635 67-78
3. Geboes K 2003 Histopathology of Crohn's disease and ulcerative colitis Inflammatory Bowel Disease 4th edn (Amsterdam: Elsevier) pp 255-76
4. Murray C D et al 2004 Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome Gastroenterology 127 1695-703 (Pubitemid 39575848)
5. Drossman D A et al 2002 AGA technical review on irritable bowel syndrome Gastroenterology 123 2108-31 (Pubitemid 35408332)
6. Green J 2006 Complications of gastrointestinal endoscopy BSG Guidelines in Gastroenterology (London: British Society of Gastroenterology) (www.bsg.org.uk/pdf-word-docs/complications.pdf)
7. Maxion-Bergemann S et al 2006 Costs of irritable bowel syndrome in the UK and US Pharmaco Economics 24 21-37 (Pubitemid 43197228)
8. Kok L 2012 Diagnostic accuracy of point-of-care faecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) study Clin. Chem. 58 989-98
9. National Institute for Health and Clinical Excellence 2008 Irritable bowel syndrome: costing report NICE Clinical Guideline 61 (London: NICE) (www.nice.org.uk/nicemedia/live/11927/39597/39597.pdf)
10. Gisbert J P, McNicholl A G and Gomollon F 2009 Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease Inflamm. Bowel Dis. 15 746-1754
11. Angriman I et al 2007 Enzymes in feces: useful markers of chronic inflammatory bowel disease Clin. Chem. Acta 381 63-68 (Pubitemid 46719135)
12. Bernstein C N et al 2010 World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010 Inflamm. Bowel Dis. 16 112-24
13. Van Rheenen P F, Van de Vijver E and Fidler V 2010 Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis BMJ 341 c3369
14. Miekisch W, Schubert J K and Noeldge-Schomburg G F 2004 Diagnostic potential of breath analysis - focus on volatile organic compounds Clin. Chim. Acta 347 25-39 (Pubitemid 39099603)
15. de Lacy Costello B and Ratcliffe N M 2013 Volatile organic compounds (VOCs) found in urine and stool Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine 1st edn, ed A Amann and D Smith (Amsterdam: Elsevier) pp 405-62
16. Arasaradnam R P et al 2011 Insights into 'fermentonomics': evaluation of volatile organic compounds (VOCs) in human disease using an electronic 'e-nose' J. Med. Eng. Technol. 35 87-91
17. Altomare D F et al 2013 Exhaled volatile organic compounds identify patients with colorectal cancer Br. J. Surg. 100 144-50
18. Walton C et al 2013 Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases Inflamm. Bowel Dis. 19 2069-78
19. Kumar S et al 2012 Selected ion flow tube-MS analysis of headspace vapor from gastric content for the diagnosis of gastro-esophageal cancer Anal. Chem. 84 9550-7
20. Garner C E et al 2007 Volatile organic compounds from faeces and their potential for diagnosis of gastrointestinal disease FASEB J. 21 1675-88 (Pubitemid 46855613)
21. Khalid T et al 2013 A pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace PloS One 8 e69602
22. Lechner M et al 2005 Headspace screening of fluid obtained from the gut during colonoscopy and breath analysis by proton transfer reaction-mass spectrometry: a novel approach in the diagnosis of gastro-intestinal diseases Int. J. Mass Spectrom. 243 151-4 (Pubitemid 40546008)
23. Jayasena H, Khalid T and Probert C S 2013 PTU-076 diagnostic potential of volatile organic compounds as faecal biomarkers in inflammatory bowel disease Gut 62 (Suppl. 1) A75-76
24. de Lacy Costello B, Shepherd S F and Ratcliffe N M 2013 The use of MS for the investigation of irritable bowel syndrome and inflammatory bowel disease Clin. Lab Int. Mag. 37 18-20
25. Meij T G et al 2013 Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study Int. J. Cancer 134 1132-8
26. De Meij T G et al 2013 Su1268 fecal gas analysis by electronic nose of pediatric IBD patients and healthy controls: a pilot study Gastroenterology 144 S443
27. Bensalah K, Montorsi F and Shariat S F 2007 Challenges of cancer biomarker profiling Eur. Urol. 52 1601-9 (Pubitemid 350052431)
28. Drucker E and Krapfenbauer K 2013 Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine EPMA J. 4 7
29. Drossman D A 1999 The functional gastrointestinal disorders and the Rome II process Gut 45 (Suppl. 2) II1-II5 (Pubitemid 29434806)
30. Walmsley R S et al 1998 A simple clinical colitis activity index Gut 43 29-32 (Pubitemid 28335486)
31. Harvey R F and Bradshaw J M 1980 A simple index of Crohn's-disease activity Lancet 315 514
32. de Lacy Costello B, Ewen R J, Ratcliffe N M and Sivanand P S 2003 Thick film organic vapour sensors based on binary mixtures of metal oxides Sensors Actuators B 92 159-66
33. Altman G and Bland J M 1994 Diagnostic tests 1: sensitivity and specificity BMJ 308 1552 (Pubitemid 24178459)
34. Caccaro R, D'Incá R and Sturniolo G C 2010 Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease Expert Rev. Clin. Immunol. 6 551-8
35. Wilson S et al 2004 Prevalence of irritable bowel syndrome: a community survey Br. J. Gen. Pract. 54 495-502 (Pubitemid 38931344)
36. Swidsinski A et al 2007 Azathioprine and mesalazine - induced effects on the mucosal flora in patients with IBD colitis Inflamm. Bowel Dis. 13 51-56 (Pubitemid 46080009)
37. Ahmed I 2014 Faecal volatile organic metabolites (VOMs) as novel diagnostic biomarkers in inflammatory bowel disease, in preparation
38. Ahmed I et al 2013 An investigation of fecal volatile organic metabolites in irritable bowel syndrome PloS One 8 e58204
39. Hrdlička L et al 2012 Analysis of volatile compounds in the breath of patients with inflammatory bowel diseases Gastroenterol. Hepatol. 66 125-30